Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. , and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the ...

Tempus AI (NASDAQ:TEM) saw its stock decline by 4% after short-selling firm Spruce Point Capital released a scathing report ...

Valued at a market cap of $9.2 billion, Tempus AI (TEM) stock went public in June 2024. Since its initial public offering, ...

New Study Shows Impact of Ambry Genetics' Patient for Life(TM) Program on Rare Disease Diagnosis Share Resize Reprints Continue reading this article with a Barron’s subscription SUBSCRIBE NOW Topics ...

Genetic counseling (GC) in the era of next generation sequencing (NGS) to diagnose microsatellite instability (MSI) and deficient mismatch repair (dMMR) expression in colorectal cancer (CRC). This is ...

New AI Tool Reveals Single-Cell Structure of Chromosomes -- In 3D May 28, 2025 — In a major leap forward for genetic and biomedical research, scientists have developed a powerful new artificial ...